NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, July 08, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced upcoming presentations at the annual Alzheimer's Association International Conference (AAIC), taking place at the Excel London Convention & Exhibition Centre, in London, UK, and online, on July 11-15, 2026, showcasing biomarker technologies from DiamiR's CLIA-certified, CAP-accredited clinical laboratory.
Alidad Mireskandari, Ph.D., Chief Executive Officer of DiamiR, will make the following presentations:
Abstract Title: Plasma-based APOE Genotyping: Development and Optimization of A Robust Protocol
Poster Number: 1160
Session Title: Developing Topics: Biomarkers
Date and Time: Sunday, July 12, 2026, 7:30 AM to 4:15 PM BST
Abstract Title: Circulating Brain-enriched And Inflammatory MicroRNAs As Blood Biomarkers Of Mild Cognitive Impairment To Alzheimer's Progression
Poster Number: 1037
Session Title: Developing Topics: Biomarkers
Date and Time: Sunday, July 12, 2026, 7:30 AM to 4:15 PM BST
Abstract Title: Automated APOE Genotyping Directly from Blood and Buccal Specimens Without DNA Isolation: A Point-of-Care Ready Approach
Poster Number: 1282
Session Title: Developing Topics: Basic Science and Pathogenesis
Date and Time: Tuesday, July 14, 2026, 7:30 AM to 4:15 PM BST
About Alzheimer's Association International Conference
The AAIC is the world's largest gathering dedicated to advancing dementia science. Each year, AAIC convenes the world's leading basic scientists, clinical researchers, early-career investigators, clinicians, and the care research community to share groundbreaking research discoveries that will lead to methods of prevention and treatment, and improvements in diagnosis for Alzheimer's disease and related dementias.
About Aptorum Group
Aptorum Group Limited (Nasdaq: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. For more information, please visit the company's website at www.aptorumgroup.com.
About DiamiR Biosciences
DiamiR Biosciences Corp. is a private molecular diagnostics company focused on developing and commercializing minimally invasive tests offered through its CLIA-certified, CAP-accredited laboratory for early detection and monitoring of brain health conditions and other diseases in clinical trials and clinical practice settings. DiamiR's proprietary platform technology, protected by over 50 issued patents worldwide, is based on quantitative analysis of organ-enriched, including brain-enriched and inflammation-associated, microRNA signatures in plasma for screening, patient stratification, as well as disease progression and treatment monitoring. In addition, DiamiR offers protein and genetic biomarker analyses. DiamiR collaborates with leading academic centers, disease foundations, and biopharma companies. For more information, please visit the company's website at www.diamirbio.com and connect with DiamiR on LinkedIn.